Rucaparib: A Targeted Therapy for Ovarian and Prostate Cancer

[Daisy Miller]

Rucaparib is an oral anti-cancer drug that belongs to a class of medications known as PARP (poly ADP-ribose polymerase) inhibitors. It is primarily used in the treatment of advanced ovarian cancer and metastatic castration-resistant prostate cancer (mCRPC), particularly in patients with BRCA gene mutations. By inhibiting PARP enzymes, Rucaparib prevents cancer cells from repairing their damaged DNA, ultimately leading to cell death.

In ovarian cancer, Rucaparib is often prescribed as maintenance therapy after successful response to platinum-based chemotherapy. It helps extend progression-free survival and delays the recurrence of the disease. In prostate cancer, Rucaparib is indicated for patients with deleterious BRCA mutations who have already undergone prior hormone and chemotherapy treatments.

Rucaparib is typically taken as oral tablets and is generally well-tolerated, though common side effects may include fatigue, nausea, and anemia. Dose adjustments may be necessary depending on patient response and tolerance levels.

As global demand for advanced cancer treatments grows, sourcing Rucaparib from a reliable Rucaparib exporter becomes increasingly important. Trusted exporters ensure a consistent supply of high-quality medication that complies with international quality and regulatory standards, supporting better treatment outcomes worldwide.

[Author]

Posts